If it's on your mind and it has to do with multiple sclerosis in any way, post it here.


Postby bromley » Wed Sep 27, 2006 1:11 am

The ECTRIMS conference starts today. I attach the link to the scientific programme for each day. You can click on individual presentations / posters and see the abstracts (some are not available yet).

Art from the Boston Cure Programme is attending (I think) and usually produces an excellent summary. This will probably be available next week. I must admit, some of the abstracts are pretty dull. There's quite a bit on FTY 720 and Tysabri.

User avatar
Family Elder
Posts: 1888
Joined: Fri Sep 10, 2004 3:00 pm


Vitamin D News from Ectrims 2006

Postby Shayk » Sat Sep 30, 2006 7:53 pm

Hi all

Given the recent interest in Vitamin D I can't believe no one's posted this info yet from the Ectrims 2006 here it is.

Longitudinal study of serum 25-hydroxyvitamin D and PTH levels in multiple sclerosis
M. Soilu-Hänninen, M. Laaksonen, I. Laitinen, J.-P. Erälinna, E.-M. Lilius, I. Mononen (Turku, FIN)

Background: Past sun exposure and vitamin D supplementation have been associated with a reduction in the risk of multiple sclerosis (MS). In an earlier cross-sectional study we showed that newly diagnosed MS patients have lower levels of 25-hydroxyvitamin D (25[OH]D) during MS relapses than in remission. There are no previous longitudinal studies of 25(OH)D levels in MS.
Methods: We measured the serum concentrations of 25(OH)D serially during the first year of the PRISMS study in 23 MS patients and during one year in 23 individually age and sex-matched healthy controls. In MS patients, the serum 25(OH)D levels were compared with the clinical and MRI disease activity and the therapy received. To compare regulation of 25(OH)D metabolism by parathyroid hormone (PTH) between MS patients and healthy controls, serum levels of intact PTH (iPTH) were determined in these two groups.
Results: 25(OH)D and iPTH levels were similar in MS patients and healthy controls, but 25(OH)D levels were lower and iPTH levels were higher during MS relapses than in remission. All 21 relapses identified during the study occurred at PTH levels above 20 ng/L, whereas 38% of patients in remission had PTH less or equal to 20 ng/L There was no correlation with 25(OH)D or iPTH levels and MRI BOD or T2 activity. Interferon-beta had no effect on the serum levels of 25(OH) D or iPTH.
Conclusion: Vitamin D is a potential regulator of the clinical disease activity in MS. Elevation of intact PTH above 20 ng/L is an indicator of a risk for MS relapse.

User avatar
Family Elder
Posts: 785
Joined: Fri Feb 06, 2004 4:00 pm

Return to General Discussion


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service